Amneal Pharmaceuticals, Inc. (AMRX) financial statements (2021 and earlier)

Company profile

Business Address
,
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments341151213 
Cash and cash equivalents341151213 
Restricted cash and investments625 
Receivables669636529 
Inventory, net of allowances, customer advances and progress billings491381457 
Inventory491381457 
Prepaid expense343538 
Contract with customer, asset212
Other undisclosed current assets8441 
Total current assets:1,5521,2101,287 
Noncurrent Assets
Finance lease, right-of-use asset5961
Operating lease, right-of-use asset5970
Property, plant and equipment478478544 
Intangible assets, net (including goodwill)1,8271,8022,081 
Goodwill523420426 
Intangible assets, net (excluding goodwill)1,3051,3831,655 
Other noncurrent assets324468 
Other undisclosed noncurrent assets  373 
Total noncurrent assets:2,4542,4563,066 
TOTAL ASSETS:4,0063,6664,353 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:614507514 
Accounts payable153103115 
Accrued liabilities807766 
Employee-related liabilities593677 
Taxes payable69  
Other undisclosed accounts payable and accrued liabilities316283257 
Debt442121 
Due to related parties8618 
Other undisclosed current liabilities11150 
Total current liabilities:677550554 
Noncurrent Liabilities
Long-term debt and lease obligation2,7352,6092,670 
Long-term debt, excluding current maturities2,7352,6092,631 
Capital lease obligations39 
Liabilities, other than long-term debt864039 
Other liabilities864039 
Other undisclosed noncurrent liabilities151120194 
Total noncurrent liabilities:2,9722,7692,903 
Total liabilities:3,6493,3193,456 
Temporary equity, carrying amount12   
Stockholders' equity
Stockholders' equity attributable to parent, including:303232505 
Common stock   0
Additional paid in capital628607530 
Accumulated other comprehensive loss(41)(0)(8) 
Accumulated deficit(287)(378)(21) 
Receivable from shareholders or affiliates for issuance of capital stock   (0)
Other undisclosed stockholders' equity attributable to parent333 
Stockholders' equity attributable to noncontrolling interest42115392 
Total stockholders' equity:345347896 
TOTAL LIABILITIES AND EQUITY:4,0063,6664,353 

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1,9931,6261,663 
Cost of revenue
(Cost of Goods and Services Sold)
(1,330)(1,147)(947) 
Other undisclosed gross profit(35)(126)  
Gross profit:628353716 
Operating expenses(537)(602)(533) 
Other undisclosed operating loss  (203) 
Operating income (loss):91(249)(20) 
Nonoperating income (expense)(127)28(183) 
Investment income, nonoperating07(3) 
Foreign currency transaction gain (loss), before tax16(5)(20) 
Interest and debt expense(9)(6)(6) 
Loss from continuing operations before equity method investments, income taxes:(44)(227)(209) 
Other undisclosed income from continuing operations before income taxes966 
Loss from continuing operations before income taxes:(36)(220)(203) 
Income tax expense (benefit)104(383)1 
Net income (loss):69(604)(201) 
Net income attributable to noncontrolling interest2224233 
Other undisclosed net income attributable to parent  149 
Net income (loss) attributable to parent:91(362)(20) 
Preferred stock dividends and other adjustments  (1) 
Net income (loss) available to common stockholders, diluted:91(362)(21) 

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):69(604)(201) 
Comprehensive income (loss):69(604)(201) 
Comprehensive income, net of tax, attributable to noncontrolling interest6523236 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(84)19142 
Comprehensive income (loss), net of tax, attributable to parent:50(353)(23) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: